Keywords: وندتانیب; Cabozantinib; Medullary; Metastatic; Multikinase; REMS; Vandetanib;
مقالات ISI وندتانیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: وندتانیب; Vandetanib; Lysozyme; Vandetanib-lysozyme interaction; Circular dichroism; Molecular dynamics;
Keywords: وندتانیب; Polymeric nanomedicines; Peptide; Cancer therapy; Therapeutic delivery; AF; aminoflavone; ANG; angiopep-2; BBB; blood brain barrier; BCECs; brain capillary endothelial cells; BP; bortezomib-pinanediol; bPEISS; bioreducible branched polyethylenimine; BPLP;
Keywords: وندتانیب; Antineoplastic agents/adverse effects; Angiogenesis inhibitors; Cardiotoxins; Vascular endothelial growth factor; Bevacizumab; Sorafenib; Sunitinib; Vandetanib; Aflibercept;
Keywords: وندتانیب; medullary thyroid cancer; RET; tyrosine kinase inhibitors; vandetanib; cabozantinib; chemotherapy;
Keywords: وندتانیب; Bunyaviridae; Andes virus; Hantavirus pulmonary syndrome; Antiviral; Animal model; Hemorrhagic fever; Vascular endothelial growth factor; Vandetanib; Tyrosine kinase inhibitor;
Keywords: وندتانیب; Medullary thyroid cancer; RET mutations; Vandetanib; Cabozantinib; Tyrosine kinase inhibitors
Keywords: وندتانیب; Cancer; Gastrointestinal perforation; Sorafenib; Sunitinib; Vandetanib; Axitinib; Pazopanib; Cediranib; Meta-analysis;
Keywords: وندتانیب; Meta-analysis; non-small cell lung cancer; overall response rate; overall survival; progression-free survival; randomised controlled trials; vandetanib;
An alternative synthesis of Vandetanib (Caprelsaâ¢) via a microwave accelerated Dimroth rearrangement
Keywords: وندتانیب; Vandetanib; Quinazoline; Dimroth rearrangement; Tyrosine kinase inhibitor;
Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies
Keywords: وندتانیب; MTKi; multi-tyrosine kinase inhibitor; RODEB; radiopaque drug-eluting bead; HCC; hepatocellular carcinoma; Vandetanib; Tyrosine kinase inhibitors; Drug-eluting beads; Transarterial chemoembolization;
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases
Keywords: وندتانیب; RET; mTOR; Lung cancer; Brain metastases; Next generation sequencing; Vandetanib; Everolimus; Exceptional responder;
Thyroid Gland Malignancies
Keywords: وندتانیب; Anaplastic; Medullary; Differentiated; Thyroid cancer; Cabozantinib; Lenvatinib; Sorafenib; Vandetanib;
Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Elderly Patients
Keywords: وندتانیب; Vandetanib; Gemcitabine; Non-small-cell lung cancer; Elderly;
Vandetanib-induced phototoxicity in human keratinocytes NCTC-2544
Keywords: وندتانیب; Vandetanib; Phototoxicity; Photoproducts; DNA photodamage; Apoptosis; Photolysis;
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904
Keywords: وندتانیب; Ovarian cancer; Primary peritoneal cancer; Fallopian tube cancer; Epithelial cancer; Chemotherapy; Taxanes; Vandetanib; Clinical trial; Randomised phase II;
Isolation and structure elucidation of the main UV-A photoproducts of vandetanib
Keywords: وندتانیب; Vandetanib; Photoproduct; Photostability; Phototoxicity; HPLC;
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy
Keywords: وندتانیب; Vandetanib; Maintenance; Chemotherapy; Lung cancer; Progression-free survival; Target therapy;
Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial
Keywords: وندتانیب; Vandetanib; Non–small-cell lung cancer; EGFR mutation; EGFR gene amplification
Vandetanib Plus Chemotherapy for Induction Followed by Vandetanib or Placebo As Maintenance for Patients with Advanced Non–Small-Cell Lung Cancer: A Randomized Phase 2 PrECOG Study (PrE0501)
Keywords: وندتانیب; Vandetanib; Non–small-cell lung cancer; Maintenance therapy
Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines 1
Keywords: وندتانیب; Prostate cancer; Vandetanib; Docetaxel; Epidermal growth factor receptor (EGFR); VEGFR; VEGFA
Actualités thérapeutiques : l'abiratérone, le bélatacept, le vandétanib et la fidaxomycine
Keywords: وندتانیب; Abiratérone; Sipuleucel T; Dénosumab; Cabazitaxel; Enzulatamide; Alpharadin; Bélatacept; Vandétanib; Fidaxomycine; Abiraterone; Sipuleucel T; Denosumab; Cabazitaxel; Enzulatamide; Alpharadin; Belatacept; Vandetanib; Fidaxomicin;
Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line
Keywords: وندتانیب; HRPC; PC3 cell line; Vandetanib; Docetaxel; Combination treatment
Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad
Keywords: وندتانیب; RET fusion; Lung adenocarcinoma; Cell line; Vandetanib
Emerging therapies for thyroid carcinoma
Keywords: وندتانیب; Thyroid carcinoma; Tyrosine kinase inhibitors; Papillary; Medullary; Anaplastic; BRAF; RET; Vandetanib; Sunitinib; Sorafenib; Imatinib; Motesanib
Phase I Dose Escalation Trial of Vandetanib With Fractionated Radiosurgery in Patients With Recurrent Malignant Gliomas
Keywords: وندتانیب; Vandetanib; Recurrent malignant glioma; Stereotactic radiosurgery; SRS;
Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis
Keywords: وندتانیب; Cancer; Renal cell cancer; Vascular endothelial growth factor; Sunitinib; Sorafenib; Pazopanib; Vandetanib; Meta-analysis; Mortality; Fatal adverse events;
Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin
Keywords: وندتانیب; Vandetanib; Tyrosine kinase inhibitor; Multidrug resistance; P-glycoprotein; Reversion
Epidermal Growth Factor Receptor Expression Modulates Antitumor Efficacy of Vandetanib or Cediranib Combined With Radiotherapy in Human Glioblastoma Xenografts
Keywords: وندتانیب; Vandetanib; Cediranib; Radiotherapy; wtEGFR; Glioblastoma;
Personalised medicineCo-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors
Keywords: وندتانیب; P-glycoprotein; Breast cancer resistant protein; Vandetanib; Brain; Efflux; Pharmacokinetics;
Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy Subjects
Keywords: وندتانیب; disposition; metabolism; pharmacokinetics; vandetanib
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma
Keywords: وندتانیب; PD173074; Sunitinib; Vandetanib; Vatalanib; FGFR3; Multiple myeloma
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
Keywords: وندتانیب; Clinical trial; Phase I; Vandetanib; Bevacizumab; VEGF inhibitor; EGF inhibitor; ZD6474;
Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumors: An Open-Label, Phase I, Rising Multiple-Dose Study
Keywords: وندتانیب; cancer; Chinese patients; pharmacokinetics; tolerability; vandetanib
A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer
Keywords: وندتانیب; NSCLC; Vandetanib; Combination; Chemotherapy; Pharmacokinetics
Phase I Study of Vandetanib With Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma
Keywords: وندتانیب; Glioblastoma; vandetanib; radiotherapy; temozolomide;
Methodological aspects of lung cancer clinical trials in the era of targeted agents
Keywords: وندتانیب; Lung cancer; Clinical trial methodology; Erlotinib; Gefitinib; Vandetanib; Sorafenib; Bevacizumab; Cetuximab
Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
Keywords: وندتانیب; Antiangiogenesis; Axitinib; BIBF 1120; Cediranib; Dose-finding study; Metastatic NSCLC; Motesanib; Pazopanib; PDGFR; Sorafenib; Sunitinib; Vandetanib; Vatalanib; VEGFR; XL647; XL999;
Combination of Vandetanib, Radiotherapy, and Irinotecan in the LoVo Human Colorectal Cancer Xenograft Model
Keywords: وندتانیب; Vandetanib; Radiotherapy; CPT-11; LoVo colorectal cancer; Angiogenesis inhibitor;
A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer
Keywords: وندتانیب; Non-small cell lung cancer; Vandetanib; EGFR; VEGFR
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement
Keywords: وندتانیب; Malignant pleural mesothelioma; Vandetanib; VEGF; RET; Tyrosine kinase inhibitors
A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors
Keywords: وندتانیب; Phase I study; ZD6474; Vandetanib; Non-small cell lung cancer